The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

Temsahy, Mona M. El; Kerdany, Eman D. H. El; Eissa, Maha M.; Shalaby, Thanaa I.; Talaat, Iman M.; Mogahed, Nermine Mogahed Fawzy Hussein

doi:10.1007/s12639-014-0546-z

Cited by 34 publications

(32 citation statements)

References 50 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, N. sativa seeds essential oil was recently found to have antihelmenthic activity against S. mansoni infection (Mahmoud et al, 2002). Many studies used nanoparticles as vehicles to deliver drugs for the improvement of their therapeutic efficacy (El-Temsahy et al, 2016). In this study, we used chitosan as a drug carrier for N. sativa to improve its efficacy.…”

Section: Discssionmentioning

confidence: 99%

In vitro effect and scanning electron microscopic changes of Nigella sativa loaded chitosan nanoparticles on Schistosoma mansoni adult

Kishik¹,

Mohram²,

Nagib³

et al. 2019

J. Med. Plants Res.

View full text Add to dashboard Cite

Nanoparticles can act as drug carriers that can modulate pharmacokinetics, increase bioavailability and target release with minimal toxic effects. The present work aimed to assess the therapeutic effect and electron microscopic changes of Nigella sativa loaded Chitosan Nanoparticles (NSLCN) on adult Schistosoma mansoni in vitro. Adult worms were removed from the portal and mesenteric veins of infected mice after 90 days, and then three to five mature worms including both sexes were cultured. Schistosoma adult was exposed to NSLCN at concentrations of (10, 20, 40, 60, 80, and 100 μg/ml) for 24, and 48 h. Examination for worm viability was done after 24, and 48 h using a stereomicroscope comparing with control negative and control positive groups. The mortality rate in worms reached 88.9% in the group treated with 100 μg and 80 and 84.6% in groups treated with 80 and 60 μg respectively (p-value <0.001). After 48 h of incubation with the same concentration, there were variable effects on motility and death of worms, the death rate reached 100% in all groups treated with nanoparticles. After 24 h incubation, the live worms have sluggish motility and reached dead score at 48 h of incubation. By (SEM) there were tegumental changes of both dead male and female in the form of loss of spines, swollen suckers and swollen inter tubercular ridges in male and loss of smooth architecture of female tegument with multiple pores. In conclusion, NSLCN appears as a new potential candidate drug against schistosomiasis. We successfully applied nanoemulsion preparation against the adult stage of S. mansoni in vitro.

show abstract

Section: Discssionmentioning

confidence: 99%

In vitro effect and scanning electron microscopic changes of Nigella sativa loaded chitosan nanoparticles on Schistosoma mansoni adult

Kishik¹,

Mohram²,

Nagib³

et al. 2019

J. Med. Plants Res.

View full text Add to dashboard Cite

show abstract

“…Results of spleen tissue examination of infected control group (G2) showed the presence of tissue cysts in large numbers and pseudocysts of Toxoplasma. El Temsahy et al, [55] revealed the presence of Toxoplasma pseudocysts containing viable tachyzoites in spleen tissue of mice, using experimental infection by virulent RH strain. In SPF treated group (G3), spleen tissue showed decreased number of tissue cysts as compared to control group (G2), attributed to the synergistic effect of the drug (SPF) on nucleic acid synthesis in Toxoplasma.…”

Section: Discussionmentioning

confidence: 99%

The Outcomes of Mesenchymal Stem Cells Therapy for Experimental Toxoplasmosis

Etewa

Al-Hoot

Abdelmoaty

et al. 2019

Parasitologists United Journal

View full text Add to dashboard Cite

“…Chitosan is a non-toxic, biodegradable, biocompatible natural polysaccharide and it was approved by the Food and Drug Administration (FDA) as a safe adjuvant and vaccine delivery system [150,151]. In addition, the chitosan formulation was able to improve the immunogenicity of a peptide-based vaccine and induced an immune response mediated by IgG2a [152].…”

Section: Development Of Pneumococcal Nanovaccinesmentioning

confidence: 99%

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

et al. 2020

View full text Add to dashboard Cite

Streptococcus pneumoniae is a major pathogen causing pneumonia with over 2 million deaths annually, especially in young children and the elderly. To date, at least 98 different pneumococcal capsular serotypes have been identified. Currently, the vaccines for prevention of S. pneumoniae infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV23) and the pneumococcal conjugate vaccines (PCV10 and PCV13). These vaccines only cover some pneumococcal serotypes and are unable to protect against non-vaccine serotypes and unencapsulated S. pneumoniae. This has led to a rapid increase in antibiotic-resistant non-vaccine serotypes. Hence, there is an urgent need to develop new, effective, and affordable pneumococcal vaccines, which could cover a wide range of serotypes. This review discusses the new approaches to develop effective vaccines with broad serotype coverage as well as recent development of promising pneumococcal vaccines in clinical trials. New vaccine candidates are the inactivated whole-cell vaccine strain (Δpep27ΔcomD mutant) constructed by mutations of specific genes and several protein-based S. pneumoniae vaccines using conserved pneumococcal antigens, such as lipoprotein and surface-exposed protein (PspA). Among the vaccines in Phase 3 clinical trials are the pneumococcal conjugate vaccines, PCV-15 (V114) and 20vPnC. The inactivated whole-cell and several protein-based vaccines are either in Phase 1 or 2 trials. Furthermore, the recent progress of nanoparticles that play important roles as delivery systems and adjuvants to improve the performance, as well as the immunogenicity of the nanovaccines, are reviewed.

show abstract

The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

Cited by 34 publications

References 50 publications

In vitro effect and scanning electron microscopic changes of Nigella sativa loaded chitosan nanoparticles on Schistosoma mansoni adult

In vitro effect and scanning electron microscopic changes of Nigella sativa loaded chitosan nanoparticles on Schistosoma mansoni adult

The Outcomes of Mesenchymal Stem Cells Therapy for Experimental Toxoplasmosis

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

Contact Info

Product

Resources

About